<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02222506</url>
  </required_header>
  <id_info>
    <org_study_id>CL-K1002-P009</org_study_id>
    <nct_id>NCT02222506</nct_id>
  </id_info>
  <brief_title>Safety Evaluation of the KLOX BioPhotonic System in Diabetic Foot Ulcers</brief_title>
  <official_title>A Prospective Case Series Evaluating the Safety of the KLOX BioPhotonic System in Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KLOX Technologies Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KLOX Technologies Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of these case series is to evaluate the safety and tolerability of the&#xD;
      KLOX BioPhotonic System as adjunctive therapy to Standard Of Care (SOC) in patients with&#xD;
      diabetic foot ulcers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of the KLOX BioPhotonic System in patients with diabetic foot ulcers.</measure>
    <time_frame>32 weeks</time_frame>
    <description>Occurrence of adverse events, serious adverse events and incidents; pain assessment with Visual Analog Scale; clinical laboratory parameters; vital signs; physical examination; percentage of patients with clinical infection requiring systemic antimicrobial therapy; concomitant medications and treatments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Optimal frequency of treatment with KLOX BioPhotonic System on diabetic foot ulcers.</measure>
    <time_frame>32 weeks</time_frame>
    <description>Exploration of the optimal frequency of treatment with KLOX BioPhotonic System on diabetic foot ulcers, with dosing flexibility according to Investigator's clinical opinion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complete wound closure.</measure>
    <time_frame>32 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete wound closure.</measure>
    <time_frame>32 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of wound breakdown.</measure>
    <time_frame>32 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound area reduction over time.</measure>
    <time_frame>32 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound volume reduction over time.</measure>
    <time_frame>32 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Impact of treatment on Health-related quality of life.</measure>
    <time_frame>32 weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Diabetic Foot Ulcers</condition>
  <arm_group>
    <arm_group_label>KLOX BioPhotonic System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with KLOX BioPhotonic System in adjunction to Standard Of Care for diabetic foot ulcers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>KLOX BioPhotonic System</intervention_name>
    <description>KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 24 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for diabetic foot ulcers.</description>
    <arm_group_label>KLOX BioPhotonic System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female 18 years of age and older;&#xD;
&#xD;
          -  The subject or legal guardian must have signed an informed consent form;&#xD;
&#xD;
          -  Female of child bearing potential must have a negative pregnancy test result at&#xD;
             Baseline and both male and female patients must be willing to adhere to a&#xD;
             medically-accepted birth control method during the course of the study;&#xD;
&#xD;
          -  Willingness to return for all study visits;&#xD;
&#xD;
          -  Willing and able to adhere to an off-loading protocol. Patient must adhere to wearing&#xD;
             orthopedic shoe for the study duration (from first day of Screening until end of&#xD;
             study);&#xD;
&#xD;
          -  Target cutaneous, full thickness ulcer with University of Texas classification I-A&#xD;
             (superficial, non-infected, non-ischemic wound not involving tendon, capsules, or&#xD;
             bone) or II-A (non-infected, non-ischemic wound penetrating to tendon or capsule but&#xD;
             not in the bone or joint). A patient with more than one diabetic foot ulcer may be&#xD;
             included in the trial but only one ulcer will be selected for the investigational&#xD;
             treatment, based on investigator's judgment;&#xD;
&#xD;
          -  Ulcer present for more than 4 weeks prior to study entry (Screening/Visit 1);&#xD;
&#xD;
          -  Ulcer area between 1 and 16 cm2 inclusive. The maximum diameter of the wound must not&#xD;
             exceed 8 cm;&#xD;
&#xD;
          -  Diabetes mellitus (Type 1 or 2) with an A1C &lt; 12% at Screening;&#xD;
&#xD;
          -  Diagnosis of neuropathic foot ulcer (10 grams pressure using Semmes-Weinstein 5.07&#xD;
             monofilament in the peri-ulcer area and/or biothesiometry or tuning fork 128 Hz);&#xD;
&#xD;
          -  Wound area has not changed by more than +/- 30% between Screening visit and Week&#xD;
             1/Visit 1 (before treatment).&#xD;
&#xD;
          -  Adequate arterial blood perfusion (ABI (ankle brachial index) between 0.7 and 1.3,&#xD;
             inclusive, or toe pressure &gt; 50 mmHg, or tcPO2 &gt; 40 mmHg).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetic foot ulcer present for more than 12 months;&#xD;
&#xD;
          -  Target ulcer is over a deformity (such as Charcot deformity) that interferes with&#xD;
             off-loading based on investigator's opinion;&#xD;
&#xD;
          -  Patient cannot tolerate off-loading method;&#xD;
&#xD;
          -  The ulcer to be treated is planned for operative debridement;&#xD;
&#xD;
          -  The ulcer has significant necrotic tissue (e.g., more than 20% of the ulcer area);&#xD;
&#xD;
          -  Major uncontrolled medical disorder(s) such as serious cardiovascular, renal, liver or&#xD;
             pulmonary disease, lupus, palliative care or sickle cell anemia;&#xD;
&#xD;
          -  Severe or significant hypoalbuminemia (albuminemia &lt; 30 g/L, and/or pre-albumin &lt; 5&#xD;
             mg/dL), or hypoproteinemia (proteinemia &lt; 55g/L);&#xD;
&#xD;
          -  Patient with moderate to severe anemia (Hb &lt; 90g/L);&#xD;
&#xD;
          -  Patient currently treated for an active malignant disease;&#xD;
&#xD;
          -  Patient with history of malignancy within the wound;&#xD;
&#xD;
          -  Patient with history of radiation therapy to the wound region;&#xD;
&#xD;
          -  Patient with prior diagnosis of active malignant disease who is less than 1 year&#xD;
             disease-free;&#xD;
&#xD;
          -  Patient with a known osteomyelitis or active cellulitis;&#xD;
&#xD;
          -  Patients that are immunosuppressed or on high dose chronic steroid use;&#xD;
&#xD;
          -  Patients on systemic corticosteroids (a completion of corticosteroid course at least&#xD;
             30 days prior to study enrolment is required);&#xD;
&#xD;
          -  Patient with active or systemic infection (note that the patient is however eligible&#xD;
             for re-screening after the systemic infection has subsided);&#xD;
&#xD;
          -  Successful revascularization surgery of the leg with the ulcer to be treated less than&#xD;
             8 weeks prior to Screening;&#xD;
&#xD;
          -  Patients with severely uncontrolled diabetes mellitus (defined as A1C &gt; 12%);&#xD;
&#xD;
          -  Raynaud disease or other severe peripheral microvascular disease;&#xD;
&#xD;
          -  Dermatologic comorbid disease (e.g., cutis laxa or collagen vascular disease);&#xD;
&#xD;
          -  Active bleeding;&#xD;
&#xD;
          -  Pregnancy, or breast feeding;&#xD;
&#xD;
          -  Patients with bleeding diathesis;&#xD;
&#xD;
          -  Patients on Warfarin or IV Heparin;&#xD;
&#xD;
          -  The subject has any physical or psychiatric condition that in the Investigator's&#xD;
             opinion would warrant exclusion from the study or prevent the subject from completing&#xD;
             the study (e.g., severe morbid obesity, recent hip fracture, suspected non-compliance,&#xD;
             etc.);&#xD;
&#xD;
          -  Patients with ulcers from burns (from exposure to high heat), pressure ulcers or&#xD;
             venous leg ulcers;&#xD;
&#xD;
          -  Concurrent disease or drugs known to induce severe photosensitivity of the skin, such&#xD;
             as porphyria;&#xD;
&#xD;
          -  Patient has received biological-based therapy in any wound within 3 months of&#xD;
             Screening;&#xD;
&#xD;
          -  Concurrent participation in another clinical trial that involves an investigational&#xD;
             drug or device that wound interfere with this study;&#xD;
&#xD;
          -  Previous participation in other interventional wound healing clinical investigation&#xD;
             within the 60 days prior to Screening visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Nikolis, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Victoria Park MediSpa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Q&amp;T Research Chicoutimi</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 7Y8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Clinique de Laval</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7T 2P5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victoria Park MediSpa</name>
      <address>
        <city>Westmount</city>
        <state>Quebec</state>
        <zip>H3Z 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>August 19, 2014</study_first_submitted>
  <study_first_submitted_qc>August 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2014</study_first_posted>
  <last_update_submitted>September 1, 2016</last_update_submitted>
  <last_update_submitted_qc>September 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

